Literature DB >> 27886451

Activity of Fluorine-Containing Analogues of WC-9 and Structurally Related Analogues against Two Intracellular Parasites: Trypanosoma cruzi and Toxoplasma gondii.

María N Chao1, Catherine Li2, Melissa Storey2, Bruno N Falcone1, Sergio H Szajnman1, Sergio M Bonesi3, Roberto Docampo2, Silvia N J Moreno2, Juan B Rodriguez1.   

Abstract

Two obligate intracellular parasites, Trypanosoma cruzi, the agent of Chagas disease, and Toxoplasma gondii, an agent of toxoplasmosis, upregulate the mevalonate pathway of their host cells upon infection, which suggests that this host pathway could be a potential drug target. In this work, a number of compounds structurally related to WC-9 (4-phenoxyphenoxyethyl thiocyanate), a known squalene synthase inhibitor, were designed, synthesized, and evaluated for their effect on T. cruzi and T. gondii growth in tissue culture cells. Two fluorine-containing derivatives, the 3-(3-fluorophenoxy)- and 3-(4-fluorophenoxy)phenoxyethyl thiocyanates, exhibited half-maximal effective concentration (EC50 ) values of 1.6 and 4.9 μm, respectively, against tachyzoites of T. gondii, whereas they showed similar potency to WC-9 against intracellular T. cruzi (EC50 values of 5.4 and 5.7 μm, respectively). In addition, 2-[3- (phenoxy)phenoxyethylthio]ethyl-1,1-bisphosphonate, which is a hybrid inhibitor containing 3-phenoxyphenoxy and bisphosphonate groups, has activity against T. gondii proliferation at sub-micromolar levels (EC50 =0.7 μm), which suggests a combined inhibitory effect of the two functional groups.
© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antiprotozoal agents; drug discovery; enzymes; fluorine; inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27886451      PMCID: PMC5200956          DOI: 10.1002/cmdc.201600505

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  48 in total

1.  Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation.

Authors:  S H Szajnman; W Yan; B N Bailey; R Docampo; E Elhalem; J B Rodriguez
Journal:  J Med Chem       Date:  2000-05-04       Impact factor: 7.446

2.  Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana.

Authors:  Julio A Urbina; Juan Luis Concepcion; Salomé Rangel; Gonzalo Visbal; Renee Lira
Journal:  Mol Biochem Parasitol       Date:  2002 Nov-Dec       Impact factor: 1.759

Review 3.  New antibacterials for the treatment of toxoplasmosis; a patent review.

Authors:  Juan Bautista Rodriguez; Sergio Hernán Szajnman
Journal:  Expert Opin Ther Pat       Date:  2012-03-10       Impact factor: 6.674

4.  Genetic evidence that an endosymbiont-derived endoplasmic reticulum-associated protein degradation (ERAD) system functions in import of apicoplast proteins.

Authors:  Swati Agrawal; Giel G van Dooren; Wandy L Beatty; Boris Striepen
Journal:  J Biol Chem       Date:  2009-10-06       Impact factor: 5.157

5.  A versatile catalyst system for Suzuki-Miyaura cross-coupling reactions of C(sp(2))-tosylates and mesylates.

Authors:  Brijesh Bhayana; Brett P Fors; Stephen L Buchwald
Journal:  Org Lett       Date:  2009-09-03       Impact factor: 6.005

6.  Design, synthesis, and biological evaluation of new growth inhibitors of Trypanosoma cruzi (epimastigotes).

Authors:  A J Schvartzapel; L Zhong; R Docampo; J B Rodriguez; E G Gros
Journal:  J Med Chem       Date:  1997-07-18       Impact factor: 7.446

7.  Head-to-head prenyl tranferases: anti-infective drug targets.

Authors:  Fu-Yang Lin; Yi-Liang Liu; Kai Li; Rong Cao; Wei Zhu; Jordan Axelson; Ran Pang; Eric Oldfield
Journal:  J Med Chem       Date:  2012-05-01       Impact factor: 7.446

8.  Toxoplasmosis: a persisting challenge.

Authors:  C G Lüder; W Bohne; D Soldati
Journal:  Trends Parasitol       Date:  2001-10

9.  Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.

Authors:  Kovi Bessoff; Adam Sateriale; K Kyungae Lee; Christopher D Huston
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

10.  Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition.

Authors:  I Coppens; A P Sinai; K A Joiner
Journal:  J Cell Biol       Date:  2000-04-03       Impact factor: 10.539

View more
  1 in total

Review 1.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.